These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36275757)

  • 1. Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology.
    Cognasse F; Hamzeh-Cognasse H; Duchez AC; Shurko N; Eyraud MA; Arthaud CA; Prier A; Heestermans M; Hequet O; Bonneaudeau B; Rochette-Eribon S; Teyssier F; Barlet-Excoffier V; Chavarin P; Legrand D; Richard P; Morel P; Mooney N; Tiberghien P
    Front Immunol; 2022; 13():1034379. PubMed ID: 36275757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody profiles in COVID-19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment.
    Bagri A; de Assis RR; Tsai CT; Simmons G; Mei ZW; Von Goetz M; Gatmaitan M; Stone M; Di Germanio C; Martinelli R; Darst O; Rioveros J; Robinson PV; Ward D; Ziman A; Seftel D; Khan S; Busch MP; Felgner PL; Corash LM
    Transfusion; 2022 Mar; 62(3):570-583. PubMed ID: 35128658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the impact of pathogen reduction technologies on the neutralizing activity of COVID-19 convalescent plasma.
    Hindawi S; Elgemmezi T; A El-Kafrawy S; Samadani H; Tilmisani M; Assiri O; Raml M; I Azhar E; Badawi M
    Transfus Apher Sci; 2023 Jun; 62(3):103688. PubMed ID: 36922242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study.
    Cognasse F; Hamzeh-Cognasse H; Rosa M; Corseaux D; Bonneaudeau B; Pierre C; Huet J; Arthaud CA; Eyraud MA; Prier A; Duchez AC; Ebermeyer T; Heestermans M; Audoux-Caire E; Philippot Q; Le Voyer T; Hequet O; Fillet AM; Chavarin P; Legrand D; Richard P; Pirenne F; Gallian P; Casanova JL; Susen S; Morel P; Lacombe K; Bastard P; Tiberghien P
    EBioMedicine; 2023 Jan; 87():104414. PubMed ID: 36535107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19.
    Körper S; Schrezenmeier EV; Rincon-Arevalo H; Grüner B; Zickler D; Weiss M; Wiesmann T; Zacharowski K; Kalbhenn J; Bentz M; Dollinger MM; Paul G; Lepper PM; Ernst L; Wulf H; Zinn S; Appl T; Jahrsdörfer B; Rojewski M; Lotfi R; Dörner T; Jungwirth B; Seifried E; Fürst D; Schrezenmeier H
    Front Immunol; 2022; 13():1008438. PubMed ID: 36275695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology.
    Yonemura S; Hartson L; Dutt TS; Henao-Tamayo M; Goodrich R; Marschner S
    Vox Sang; 2021 Nov; 116(10):1076-1083. PubMed ID: 33835489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amotosalen-HCl-UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin-27, the cytokines that generally associate with serious adverse events.
    Hamzeh-Cognasse H; Laradi S; Osselaer JC; Cognasse F; Garraud O
    Vox Sang; 2015 Feb; 108(2):205-7. PubMed ID: 25334045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light.
    Larrea L; Castro E; Navarro L; Vera B; Francés-Gómez C; Sánchez-Sendra B; Giménez Á; Castelló E; Collado M; Vayá MJ; Mirabet V; Callao V; Ortiz-de-Salazar MI; Roig R; Geller R; Arbona C
    Blood Transfus; 2022 May; 20(3):206-212. PubMed ID: 34369870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.
    Lanteri MC; Santa-Maria F; Laughhunn A; Girard YA; Picard-Maureau M; Payrat JM; Irsch J; Stassinopoulos A; Bringmann P
    Transfusion; 2020 Jun; 60(6):1319-1331. PubMed ID: 32333396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of SARS-CoV-2-independent immunoregulatory activity of COVID-19 convalescent plasma.
    Brox R; Achenbach S; Hackstein H
    Transfusion; 2021 Nov; 61(11):3087-3093. PubMed ID: 34546583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma.
    Kostin AI; Lundgren MN; Bulanov AY; Ladygina EA; Chirkova KS; Gintsburg AL; Logunov DY; Dolzhikova IV; Shcheblyakov DV; Borovkova NV; Godkov MA; Bazhenov AI; Shustov VV; Bogdanova AS; Kamalova AR; Ganchin VV; Dombrovskiy EA; Volkov SE; Drozdova NE; Petrikov SS
    Vox Sang; 2021 Jul; 116(6):665-672. PubMed ID: 33734455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency.
    Focosi D; Franchini M
    Transfus Clin Biol; 2021 May; 28(2):132-134. PubMed ID: 33675992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood Endothelial-Cell Extracellular Vesicles as Potential Biomarkers for the Selection of Plasma in COVID-19 Convalescent Plasma Therapy.
    Amri N; Tessier N; Bégin R; Vachon L; Bégin P; Bazin R; Loubaki L; Martel C
    Cells; 2022 Oct; 11(19):. PubMed ID: 36231083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.
    Wilson JG; Simpson LJ; Ferreira AM; Rustagi A; Roque J; Asuni A; Ranganath T; Grant PM; Subramanian A; Rosenberg-Hasson Y; Maecker HT; Holmes SP; Levitt JE; Blish CA; Rogers AJ
    JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32706339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm.
    Pouladzadeh M; Safdarian M; Eshghi P; Abolghasemi H; Bavani AG; Sheibani B; Moradi Choghakabodi P; Feghhi A; Ghafourian Boroujerdnia M; Forouzan A; Jalali Far MA; Kaydani GA; Rajaei E; Amin M; Torabizadeh M; Yousefi F; Hadaddezfuli R
    Intern Emerg Med; 2021 Nov; 16(8):2181-2191. PubMed ID: 33837906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the Inflammatory Response to Severe COVID-19 Illness.
    McElvaney OJ; McEvoy NL; McElvaney OF; Carroll TP; Murphy MP; Dunlea DM; Ní Choileáin O; Clarke J; O'Connor E; Hogan G; Ryan D; Sulaiman I; Gunaratnam C; Branagan P; O'Brien ME; Morgan RK; Costello RW; Hurley K; Walsh S; de Barra E; McNally C; McConkey S; Boland F; Galvin S; Kiernan F; O'Rourke J; Dwyer R; Power M; Geoghegan P; Larkin C; O'Leary RA; Freeman J; Gaffney A; Marsh B; Curley GF; McElvaney NG
    Am J Respir Crit Care Med; 2020 Sep; 202(6):812-821. PubMed ID: 32584597
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.